News

Oct 28, 2024

Beyfortus® immunization to protect infants from RSV has begun

Sep 12, 2024

DUPIXENT® (dupilumab injection) approved in Canada for the treatment of children aged 1 year and older with eosinophilic esophagitis (EoE)

Jul 26, 2024

Fluzone® High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza

Jul 25, 2024

Ontario Ministry of Health Announces a Universal Public Program with Beyfortus® this RSV Season

Jun 18, 2024

Sanofi Canada celebrates winners of the 2024 Biogenius Competition and awards fourth annual Biogenius Grants

Photos 1

May 31, 2024

Quebec Ministry of Health Announces Universal Public Program with Beyfortus® this Upcoming RSV Season

May 30, 2024

SANOFI OPENS NEW ADVANCED VACCINES FACILITY, STRENGTHENING ITS COMMITMENT TO BIOMANUFACTURING IN CANADA

Photos 1

May 21, 2024

The National Advisory Committee on Immunization recommends BEYFORTUS® to protect all infants against RSV

Apr 18, 2024

Quebec's INESSS recommends BEYFORTUS® for the prevention of RSV for all infants 8 months of age and younger(1)

Apr 16, 2024

Sanofi Canada invests $180M CAD to build and update infrastructure to minimize environmental footprint at its Toronto Campus by 50%

Photos 1

Mar 19, 2024

2024 Sanofi Biogenius Canada Grants open for applications

Photos 1

Feb 20, 2024

JDRF Canada and Sanofi Canada partner to raise awareness about autoimmune type 1 diabetes and the critical role of screening in its early detection

Photos 1

Jan 30, 2024

Sanofi Canada is celebrating 110 years of innovative health solutions for Canadians

Jul 25, 2023

Sanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact

Jul 17, 2023

Dupixent® (dupilumab injection) receives marketing authorization for prurigo nodularis

Jul 6, 2023

Sanofi Canada awards third annual Sanofi Biogenius Canada Grants to enhance STEM learning for students

Jun 13, 2023

Sanofi Canada Celebrates Winners of the 2023 Sanofi Biogenius Canada Competition

Jun 12, 2023

Icy Hot® Partners with KidSport Canada to Help Kids Get in the Game

May 4, 2023

DUPIXENT® (dupilumab injection) is now approved in Canada for the treatment of adult and adolescent patients (12+) with Eosinophilic Esophagitis

May 1, 2023

Libtayo® (cemiplimab) in Combination with Chemotherapy now approved in Canada for the First-line Treatment of Advanced Non-small Cell Lung Cancer

May 1, 2023

Sanofi Canada and Diabetes Care Community announce a collaboration to support the emotional well-being journey of Canadians living with diabetes

Apr 24, 2023

Health Canada approves BEYFORTUS™ (nirsevimab) for the prevention of RSV disease in infants

Apr 20, 2023

DUPIXENT® (dupilumab injection) now approved in Canada for children as young as six months old with severe atopic dermatitis

Mar 21, 2023

Notice of Compliance issued regarding Rezurock(TM) (belumosudil tablets)

Mar 8, 2023

Sanofi Canada Maintains Gender Parity Certification, Achieving Platinum Level

Photos 1

Jan 18, 2023

Health Canada accepts nirsevimab regulatory submission for infant RSV

Oct 26, 2022

Canadians Encouraged to Live "In Range" to Better Manage their Diabetes

Jun 22, 2022

Sanofi to Launch Artificial Intelligence Centre of Excellence in Toronto

Jun 16, 2022

Sanofi Canada awards second annual Sanofi Biogenius Canada Grants, supporting access to hands-on STEM learning for Canadian students

Jun 15, 2022

Sanofi Canada announces winners of 2022 Sanofi Biogenius Canada Competition

Jun 14, 2022

Sanofi Canada furthers commitment to Canadians living with diabetes through mental health resources provided by MindBeacon

May 10, 2022

Sanofi Biogenius Canada Competition returns to Canada-Wide Science Fair

May 3, 2022

Sanofi achieves the third year of Gold-level Gender Parity Certification

Mar 28, 2022

Dupixent® (dupilumab injection) now approved in Canada for the treatment of severe asthma in children aged six to 11 years with type 2 inflammation

Mar 25, 2022

Libtayo® (cemiplimab) now approved in Canada for the treatment of recurrent or metastatic cervical cancer

Jan 25, 2022

Sanofi Canada named one of Forbes Canada's Best Employers for 2022

Dec 9, 2021

Sanofi Canada supports Canada's Walk of Fame in its induction of Frederick Banting, Charles Best, James Collip and John Macleod in the 100th anniversary year of their discovery of insulin

Nov 15, 2021

Nexviazyme™ (avalglucosidase alfa for injection) is now approved in Canada for patients with late-onset Pompe disease (acid α-glucosidase deficiency)

Nov 10, 2021

Canadians living with diabetes want increased mental health resources, are interested in taking a 360-approach towards holistic car

Oct 29, 2021

Libtayo® (cemiplimab) approved in Canada for locally advanced basal cell carcinoma (BCC) patients

Oct 29, 2021

Libtayo® (cemiplimab) approved in Canada for the first-line treatment of adult patients with non-small cell lung cancer expressing PD-L1 in ≥ 50% of tumour cells with no EGFR, ALK or ROS1 aberrations

Oct 13, 2021

New SARCLISA® (isatuximab for injection) Combination Now Approved by Health Canada for Adults with Relapsed and/or Refractory Multiple Myeloma

Jul 22, 2021

DUPIXENT® (dupilumab injection) receives positive recommendation from CADTH and INESSS for the treatment of severe asthma

Jul 2, 2021

Sanofi Canada continues to invest in modern diabetes research to improve outcomes for people living with diabetes

Jun 28, 2021

New Soliqua®* data shows improved blood sugar control without weight gain versus premixed insulin

Jun 17, 2021

DUPIXENT® (dupilumab injection) pre-filled pen now available in Canada, providing convenient self-administration option for people with type 2 inflammatory diseases

Jun 10, 2021

Sanofi Canada awards first annual Biogenius Grants, strengthening equity in STEM learning for Canadian students

Jun 1, 2021

Quebec extends public reimbursement of DUPIXENT® (dupilumab injection) for the treatment of moderate-to-severe atopic dermatitis to include adolescents

May 25, 2021

DUPIXENT® (dupilumab injection) now publicly reimbursed in Ontario and New Brunswick for the treatment of moderate-to-severe atopic dermatitis

Mar 31, 2021

Sanofi to build new manufacturing facility in Toronto to strengthen domestic pandemic preparedness and increase global supply of high-dose influenza vaccine

Mar 22, 2021

Sanofi Canada earns Gold-level gender parity certification for the second straight year

Feb 23, 2021

Health Canada approves DUPIXENT® (dupilumab injection) as the first biologic for the treatment of moderate-to-severe atopic dermatitis in children aged 6 to 11 years

Jan 28, 2021

Sanofi Canada launches Biogenius Grant for high schools, strengthening commitment to equity in the field of STEM learning

Jan 26, 2021

Sanofi Canada named to Forbes Canada's Best Employers list for 2021

Dec 18, 2020

Health Canada approves expanded indication for SOLIQUA®

Dec 8, 2020

Canadians living with multiple sclerosis find support during COVID-19 pandemic through dedicated social media network

Nov 17, 2020

DUPIXENT® (dupilumab injection) now approved by Health Canada for patients with severe asthma

Sep 22, 2020

Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine

Aug 18, 2020

DUPIXENT® (dupilumab injection) now approved by Health Canada for severe chronic rhinosinusitis with nasal polyposis

Jul 15, 2020

Sanofi Canada increases access to financial assistance for diabetes medications

Jul 14, 2020

DUPIXENT® (dupilumab) receives positive recommendation from INESSS for the treatment of moderate-to-severe atopic dermatitis in adolescents

Jul 8, 2020

SARCLISA™ (isatuximab for injection) now available in Canada for patients with relapsed and refractory multiple myeloma

Jun 17, 2020

Sanofi: Important Information on Plaquenil® and COVID-19

Apr 24, 2020

DUPIXENT® (dupilumab) receives positive recommendation from CADTH for moderate-to-severe atopic dermatitis

Apr 14, 2020

Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

Apr 2, 2020

First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19

Mar 2, 2020

Cablivi® (caplacizumab) approved by Health Canada for adults living with acquired thrombotic thrombocytopenic purpura (aTTP)

Jan 30, 2020

Sanofi Canada named a Top Employer in Montreal for 2020, the third similar recognition in the last six months

Nov 22, 2019

Sanofi Canada named one of Canada's Top 100 Employers for 2020

Oct 22, 2019

Patients in Quebec now have access to DUPIXENT™ for the treatment of moderate-to-severe atopic dermatitis

Oct 18, 2019

Sanofi to conduct precautionary voluntary recall of Zantac OTC in Canada and the U.S.

Photos 1

Oct 1, 2019

"Pillars of Strength" photo exhibit opens to celebrate National Seniors Day with compelling images of Canadian Seniors

Sep 27, 2019

Health Canada approves Dupixent™ as the first biologic for the treatment of adolescents with moderate-to-severe atopic dermatitis

Sep 26, 2019

Sanofi Canada receives Gold-Level Parity Certification

Photos 1

Jun 11, 2019

Canadian employers underestimate the presence of chronic disease in the workforce

Apr 11, 2019

Health Canada issues Notice of Compliance with Conditions (NOC/c) for LibtayoTM (cemiplimab), the first and only biologic for the treatment of advanced cutaneous squamous cell carcinoma (CSCC)

Oct 17, 2018

Canadians are invited to join the conversation: Raise Your Hand for Diabetes

Oct 1, 2018

Sanofi aims to topple the flu as it marks National Seniors Day with a Guinness World Record attempt

Sep 27, 2018

Canadians living with diabetes in Ontario and Manitoba now have greater access to diabetes medicine

Sep 25, 2018

Health Canada approves Lovenox® for the prevention of blood clot formation in the extra-corporeal circulation during hemodialysis in patients with end stage kidney disease (ESKD)

Studies show that Lovenox® (enoxaparin sodium) is an alternative to conventional heparin in preventing clotting during hemodialysis

Jul 10, 2018

Sanofi denounces CADTH negative recommendation that could limit treatment options for Canadians with atopic dermatitis

Jul 3, 2018

Three Canadian Researchers Receive Sanofi–CARO Award for Research in Prostate Cancer Therapies

Jun 27, 2018

Sanofi presents results from the first head-to-head study comparing Toujeo® to insulin degludec

Jun 22, 2018

Sanofi Canada Lends Support in the Fight to Eradicate Tuberculosis in Canada

Jun 13, 2018

Canadian employers underestimate the proportion of their workforce with a chronic condition and its impact

Jun 8, 2018

Canadian science prodigy winner of prestigious international competition

May 16, 2018

Canadians living with diabetes can now access a new resource to help better manage their disease

Apr 12, 2018

Sanofi to invest €350 million in Canadian vaccine facility

Apr 12, 2018

Sanofi to invest €350 million in Canadian vaccine facility

* Expansion demonstrates company’s commitment to innovation and leadership in global public health

Apr 12, 2018

New tools, support and information on insulin use now available to Canadians living with Type 2 diabetes aiming to maintain healthy blood glucose levels

Apr 11, 2018

/R E P E A T -- Media Advisory - Sanofi to announce significant investment in Canadian vaccine production facility/

Apr 10, 2018

Media Advisory - Sanofi to announce significant investment in Canadian vaccine production facility

Mar 10, 2018

Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate

Feb 23, 2018

Building bridges in the community

Sanofi Canada donates nearly $40,000 to Centraide of Greater Montreal as 2017 Season of Solidarity campaign comes to an end

Dec 12, 2017

The results of a recent study favour Toujeo® over degludec and real-world evidence confirms Toujeo®'s value

Oct 17, 2017

Insulin in People Living with Type 2 Diabetes: Initiation and Dosage

Oct 17, 2017

Insulin in People Living with Type 2 Diabetes: Initiation and Dosage

May 29, 2017

The 20th Anniversary of The Sanofi Canada Healthcare Survey reveals surprising facts

May 12, 2017

Université de Montréal Doctoral Student earns Global Nursing Innovation Award

May 1, 2017

Sanofi Genzyme Announces Approval of CerdelgaTM (eliglustat capsules) by Health Canada for Rare Genetic Condition